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INTRODUCTION 
Type 2 diabetes is a complex disorder presently affecting 
people worldwide causing serious socio-economic 
problems.The existence of experimental animal model of a 
disease aids not only the understanding of the 
pathophysiology of such disease, but also the development 
of drugs for its treatment. According to the World Health 
Organization (WHO), there are approximately 160,000 
diabetics worldwide, the number of diabetics has double in 
the last few years and is expected to double once again in 
the year 2025 . Due to its high prevalence and potential 
deleterious effect on a patient physical and psychological 
state, diabetes is a major medical concern .Over the years, 
several animal models have been developed for studying 
diabetes mellitus or testing anti-diabetic agents. These 
models include chemical, surgical (pancreatectomy) and 
genetic manipulations in several animal species to induce 
diabetes mellitus. The selection of these models to use for 
investigating the antidiabetic properties of a new 
compound may be a very difficult task especially for 
young researchers and at times leading to misinterpretation 
of data or even wrong conclusions. The selections of 
inappropriate animal models have been identified as one of 
the common problem associated with ethnobotanical 
research. The aim of the present review is to piece together 
all the various experimental models developed for studying 
diabetes mellitus, assess the merits and demerits of each 
model and highlight the precautions needed to avoid 
erroneous results during the applications of these models.  
The currently existing animal models in diabetic 
researchcan be divided in to 2  main type  : 
Insulin dependent diabetes mellitus (IDDM ) and  Non 
insulin dependent diabetes mellitus (NIDDM). 
Animal Models  
Insulin dependent diabetes mellitus -IDDM are 3 types 
which includes Chemical induced, surgically induced and 
Genetic induced. 
Non insulin dependent diabetes mellitus - NIDDM  are 
mainly 3 types  which includes(1) Chemically induced , 
(2) Genetic models – ob/ob,db/db mice, KK, KK/A y mice, 
New Zealand obese mice , ZFR, ZDR, Gk rat, Torri rat. (3) 
Sand rat (environmental component). 
Chemically induced Diabetes 
Most commonly used model for Insulin dependent diabetes 
mellitus. The chemicals used are Alloxan and 
Steptozocinwhich cause Beta cell damage. 
Alloxan model of diabetes mellitus: It is a well- known 
diabetogenic agent widely used to induce Type 11 diabetes 
in animals
1
.Alloxan is a urea derivative which causes 
selective necrosis of the pancreatic islet β-cells. Alloxan 
and its reduction product dialuric acid establish a redox 
cycle with the formation of superoxide radicals. These 
radicals undergo dismutation to hydrogen peroxide. 
Thereafter, highly reactive hydroxyl radicals are formed by 
fenton reaction. The action of reactive oxygen species with 
a simultaneous massive increase in cytosolic calcium 
concentration causes rapid destruction of betacells
2
. It is 
used to produce  experimental diabetes in animals such as 
rabbits, rats, mice and dogs. With this agent, it is possible 
to produce different grades of severity of the disease by 
varying the dose of alloxanused.Doseused for  Rat -65 
mg/kg i.v and 150 mg/kg i.p/sc , Rabbit -150mg/kg i.v , 
Beagle dog -60mg/kg i.v, Monkey -65to 200 mg/kg 
i.v.Alloxandiabetogenic action exhibits triphasic response 
ie within 2 hours after administration , 8 hours after 
administration and 24 hours after administration. Because 
of its low stability, relatively very shorter half-life (less 
than 1 min) and acidic nature of solution, intravenous route 
of administration of Alloxan is preferred. 
Thehypoglycaemic phase may be quite severe and 
therefore alloxan should not be given to fasted animals. 
The alloxan  treated animals exhibit severe 
hyperglycaemia, glucosuria, hyperlipidaemia, polyphagia, 
polydypsia and other symptoms of uncontrolled diabetes 
and do also develop various complications such as 
neuropathy, cardiomyopathy, well-marked retinopathy and 
others. Alloxan is disadvantageous as the percentage 
incidence of diabetes is quite variable and is not 
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proportionately related to increasing doses of 
alloxan
3
.Further, the incidence of ketosis and resulting 
mortality is high. The reversal of hyperglycaemia due to 
pancreatic regeneration is early and common in case of 
alloxan treated animals. Because of these limitations, 
alloxan is now almost replaced by streptozotocin for 
induction of diabetes in laboratory animals. 
Streptozotocin model of diabetismellitus:Streptozotocin is 
a synthetic nitrosoureidoglucopyranose derivative isolated 
from fermentations of streptomycesachromogenes. 
Itsnitrosourea moiety is responsible for beta celltoxicity, 
while deoxyglucose moiety facilitatestransport across the 
cell membrane. Like alloxan, theinvolvement of free 
radicals generation and resultingalteration of endogenous 
scavengers of these reactivespecies have been reported in 
Streptozotocindiabetogenecity
4
. Further, 
streptozotocincausing alkylation or breakage of 
DNAstrands and a consequent increase in the activity 
ofpoly-ADP-ribose synthetase, an enzyme depletingNAD 
in beta cells finally leading to energydeprivation and death 
of beta cells is reported. As NAD is an antioxidant which 
exerts protective effect on the cytotoxic action of 
Streptozotocin by scavenging free radicals and causes only 
minor damage to pancreatic beta cell mass producing type 
2 diabetis. 
Single dose of Streptozotocin in sterile citrate buffer (e.g. 
pH 4.5 0.1M) may be used: mice 150 mg/kg, rats 80 
mg/kg,dog 15mg/kg administered intraperitoneally.Guinea 
pigs and rabbits are resistant to streptozotocin. Diabetes 
develops gradually and may be assessed after a few days, 
usually four days for mice and seven days for rats. 
Usually, a serum glucose level of about 180 – 500 mg/dl 
indicates the induction of diabetes mellitus.Sometimes 
diabetic animals are maintained on insulin if the 
experiments are not to commence immediately to prevent 
the animals’ dead5. 
Streptozotocin is the most commonly used drugfor 
induction of diabetes in animal models 6. There are some 
disadvantages to its use in chronic experiments, especially- 
spontaneous recovery from high blood glucose levels by 
the development of functioning insulinoma and high 
incidence of kidney and liver tumours. These problems are 
due strongly to oncogenic action of 
Streptozotocin
7
.Streptozotocin is a preferred agent to 
induce experimental diabetes since it has some advantages 
over alloxan such as, relatively longer half-life (15 min), 
sustained hyperglycaemia for longer duration and the 
development of well characterized diabetic complications 
with fewer incidences of ketosis as well as mortality. 
Alloxan  andstreptozotocin diabetic animals are most 
widely used for screening the compounds including natural 
products for their insulinomimetic,insulinotropic and other 
hypoglycaemic/ antihyperglycaemic activities. 
Combination of high fat or fructose diet plus steptozotocin 
cause beta cell damageleading to progressionof  insulin 
resistance to type-2 diabetes in out bred animals. 
Surgical model of diabetis mellitus 
Another technique used to induce diabetes is complete 
removal of the pancreas (pancreatectomy). Few 
researchers have employed this model to explore effects of 
natural products with animal species such as rats, pigs, 
dogs and primates
8
.Limitation to this technique include 
high level of technical expertise ,adequate surgical room 
environment, major surgery , high risk of animal infection, 
adequate post-operative analgesia, antibiotic 
administration, supplementation with pancreatic enzymes 
to prevent malabsorption and loss of pancreatic counter 
regulatory response to hypoglycemia. More recently, 
partial pancreatectomy has been employed, but large 
resection (more than 80% in rats) is required to obtain mild 
to moderate hyperglycemia. In this case, small additional 
resection can result in significant hypoinsulinemia
9
. This 
experimental design permits to evaluate if the compound 
has some effect on insulin resistance and secretion of 
insulin. 
Genetic models of Insulin dependent diabetes mellitus 
(IDDM) 
The non obese mutant mouse has been developed BY 
Makino and colleagues in shionogi research laboratories in 
japan in 1980. The non obese mutant mouse (Akita mouse) 
has been derived from the colony of C57 BL/6 (B6)  now 
commercially available for research at Jackson Laboratory, 
Bar Harbor. The Ins2 gene is the mouse homologue of 
human preproinsulin gene. Mice possess another active 
insulin gene, Ins1, which lacks an intron present in the C-
polypeptide-encoding region. The Akita (Ins2Akita) 
spontaneous mutation (commonly referred as Mody) is an 
autosomal dominant mutation in the insulin II gene 
(Ins2)60. Ins2Akita mutation disrupts normal insulin 
processing and causes a failure in secretion of mature 
insulin, which results in early development of 
hyperglycaemia. It is characterized by hyperglycaemia, 
hypoinsulinaemia, polydipsia and polyuria, beginning 
around 3-4 wk of age. Obesity or insulitis does not 
accompany diabetes. These mutant mice respond well to 
exogenously administered insulin. The mice with reduced 
beta cell mass and absence of beta cell autoimmunity serve 
as an excellent substitute for mice made diabetic by 
treatment with certain chemical diabetogens for islet 
transplantation studies
10
. 
Genetic models for Non-Insulin dependent diabetes 
mellitus (NIDDM
11
. Example is the spontaneously 
diabetic Goto-Kakizaki rat which is a genetic lean model 
of type 11 diabetes originating from selective breeding 
over many generations of glucose-intolerant 
nondiabeticwistar rats 
12
 . Regarding type1 diabetes 
models) 
Spontaneously develop diabetic rats:  
Thesemodels permit the evaluation of the effect of a 
natural product in an animal without the interference of the 
side effects induced by chemical drugs like alloxan and 
STZ reported above. Several recent publications 
summarized the major advances in this field, the mouse 
typically presents hyperglycemia between 12 and 30 weeks 
of age, whereas in BB rats it occurs around 12 weeks of 
age. One great advantage of these models is that they can 
be employed as model of atherosclerosis which represents 
the long term complication of diabetes mellitus and can be 
tested against several natural products
13
. 
 
 
Naveen                                             Journal of Drug Delivery & Therapeutics; 2013, 3(6), 152-154    154 
© 2011, JDDT. All Rights Reserved                                                     ISSN: 2250-1177                                                        CODEN (USA): JDDTAO 
Zucker fat rat (ZFR) 
These rats resulting from the mutation on chromosome no 
5.Inherited as autosomal resistant type. Defect in signaling 
mechanism of Leptin receptorsin hypothalamus is 
responsible for development of diabetes.Contain sturdy 
beta cellcapable of maintain high insulin secretion to 
counter the insulin resistance.This model is used as model 
for obesity, Non-Insulindependent diabetesmellitus 
associatedwith typeIV hyperlipidaemia, hypertension 
,screening of  insulin sensitizers,incretinomimetics and 
anti-obesity drugs. 
Obese Rhesus Monkey 
It is a non rodent model for diabetis.Adlibitium lab diet is 
used for this model to develop diabetes.The animal 
develop obesity, insulin resistanace and 
hyperinsulinaemia.This model is used for screening of 
insulin sensitizers. 
Non obese genetic models: The models are GK rat and 
Torri rat 
GK rat : GotoKakisakirat.These rats shows defective 
development of pancreas due to inadequate production of 
PGF(pancreatic growth factor) during its foetallife.The rats 
shows fasting hyperglycemia.This model is used to  
studythe relation between reduced  cell mass  and 
occurrence of diabetis and diabetic complications like 
diabetic nephropathy.  
Torri rat 
Developed by Torri Pharmaceuticals, Japan.These rats 
shows-Hypoinsulinaemia – fibrosis in 
pancreas,hyperglycemia and glucose intolerance .This 
model is useful for study on diabetic complications like 
cataract,retinopathy and retinal detachment. 
Genetically engineered diabetic mice  
In this case, rodents may be produced to over (transgenic) 
or under (knockout)-express proteins thought to play a key 
part in glucose metabolism.Although significant advances 
in this field have arisen in recent years, especially with the 
advent of transgenic mice, there have been no studies 
carried out involving natural products on these models. 
Certainly, the high cost restricts their study in sophisticated 
protocols which explore mechanism of potential 
therapeutic agents that either stimulates pancreatic β-cell 
death. Insulin dependent diabetes mellitus (IDDM) can be 
developed by inserting into mice unique viral protein 
which then express as a self-antigen in the pancreatic islets 
of langerhans. Autoimmune mediated destruction of beta 
cells of the islets of langerhans leads to insulin dependent 
diabetes mellitus (IDDM). 
SUMMARY AND CONCLUSION 
Many of the animal models described apparently share 
similar characteristic features of type 2 diabetes and have 
allowed experimentation that would be impossible in 
humans. None of the known single species is exactly 
equivalent to human diabetes, but each model act as 
essential tool for investigating genetic, endocrine, 
metabolic, morphologic changes and underlying 
aetiopathogenic mechanisms that could also operate during 
the evolution of type 2diabetes in humans. Hence, care 
must be taken in interpretation and extrapolation of the 
results obtained from these animal models to humans. In 
the screening programme of anti-diabetic compounds, it is 
particularly important to note that some animal models are 
better suited to screen particular class of anti-diabetic 
compounds. 
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